1 |
Kenessey A and Yen SH (1993) The extent of phosphorylation of fetal tau is comparable to that of PHF-tau from Alzheimer paired helical filaments. Brain Res 629, 40-46
DOI
|
2 |
Lee G, Thangavel R, Sharma VM et al (2004) Phosphorylation of tau by fyn: implications for Alzheimer's disease. J Neurosci 24, 2304-2312
DOI
|
3 |
Cook C, Carlomagno Y, Gendron TF et al (2014) Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance. Hum Mol Genet 23, 104-116
DOI
|
4 |
Ding H, Dolan PJ and Johnson GV (2008) Histone deacetylase 6 interacts with the microtubule-associated protein tau. J Neurochem 106, 2119-2130
DOI
|
5 |
Fan SJ, Huang FI, Liou JP, Yang CR (2018) The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer's disease model. Cell Death Dis 9, 655
DOI
|
6 |
Carlomagno Y, Chung DC, Yue M et al (2017) An acetylation-phosphorylation switch that regulates tau aggregation propensity and function. J Biol Chem 292, 15277-15286
DOI
|
7 |
Julien C, Tremblay C, Emond V et al (2009) Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease. J Neuropathol Exp Neurol 68, 48-58
DOI
|
8 |
Gorsky MK, Burnouf S, Sofola-Adesakin O et al (2017) Pseudo-acetylation of multiple sites on human Tau proteins alters Tau phosphorylation and microtubule binding, and ameliorates amyloid beta toxicity. Sci Rep 7, 9984
DOI
|
9 |
Min SW, Chen X, Tracy TE et al (2015) Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat Med 21, 1154-1162
DOI
|
10 |
Tracy TE, Sohn PD, Minami SS et al (2016) Acetylated Tau Obstructs KIBRA-Mediated Signaling in Synaptic Plasticity and Promotes Tauopathy-Related Memory Loss. Neuron 90, 245-260
DOI
|
11 |
Irwin DJ, Cohen TJ, Grossman M et al (2013) Acetylated tau neuropathology in sporadic and hereditary tauopathies. Am J Pathol 183, 344-351
DOI
|
12 |
Trzeciakiewicz H, Tseng JH, Wander CM et al (2017) A Dual Pathogenic Mechanism Links Tau Acetylation to Sporadic Tauopathy. Sci Rep 7, 44102
DOI
|
13 |
Shimura H, Schwartz D, Gygi SP and Kosik KS (2004) CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival. J Biol Chem 279, 4869-4876
DOI
|
14 |
Hatakeyama S, Matsumoto M, Kamura T et al (2004) U-box protein carboxyl terminus of Hsc70-interacting protein (CHIP) mediates poly-ubiquitylation preferentially on four-repeat Tau and is involved in neurodegeneration of tauopathy. J Neurochem 91, 299-307
DOI
|
15 |
Sahara N, Murayama M, Mizoroki T et al (2005) In vivo evidence of CHIP up-regulation attenuating tau aggregation. J Neurochem 94, 1254-1263
DOI
|
16 |
Wang Y, Garg S, Mandelkow EM and Mandelkow E (2010) Proteolytic processing of tau. Biochem Soc Trans 38, 955-961
DOI
|
17 |
Joshi V, Amanullah A, Upadhyay A, Mishra R, Kumar A and Mishra A (2016) A Decade of Boon or Burden: What Has the CHIP Ever Done for Cellular Protein Quality Control Mechanism Implicated in Neurodegeneration and Aging? Front Mol Neurosci 9, 93
|
18 |
Gupta R, Lan M, Mojsilovic-Petrovic J et al (2017) The Proline/Arginine Dipeptide from Hexanucleotide Repeat Expanded C9ORF72 Inhibits the Proteasome. eNeuro 4, e0249-16
|
19 |
Shin SK, Kim JH, Lee JH et al (2017) Docosahexaenoic acid-mediated protein aggregates may reduce proteasome activity and delay myotube degradation during muscle atrophy in vitro. Exp Mol Med 49, e287
DOI
|
20 |
Lee JH, Shin SK, Jiang Y et al (2015) Facilitated Tau Degradation by USP14 Aptamers via Enhanced Proteasome Activity. Sci Rep 5, 10757
DOI
|
21 |
Keck S, Nitsch R, Grune T and Ullrich O (2003) Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer's disease. J Neurochem 85, 115-122
DOI
|
22 |
Keller JN, Hanni KB and Markesbery WR (2000) Impaired proteasome function in Alzheimer's disease. J Neurochem 75, 436-439
|
23 |
Lopez Salon M, Morelli L, Castano EM, Soto EF and Pasquini JM (2000) Defective ubiquitination of cerebral proteins in Alzheimer's disease. J Neurosci Res 62, 302-310
DOI
|
24 |
Cardozo C and Michaud C (2002) Proteasome-mediated degradation of tau proteins occurs independently of the chymotrypsin-like activity by a nonprocessive pathway. Arch Biochem Biophys 408, 103-110
DOI
|
25 |
Zhang JY, Liu SJ, Li HL and Wang JZ (2005) Microtubule-associated protein tau is a substrate of ATP/Mg(2+)-dependent proteasome protease system. J Neural Transm 112, 547-555
DOI
|
26 |
Babu JR, Geetha T and Wooten MW (2005) Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation. J Neurochem 94, 192-203
DOI
|
27 |
de Vrij FM, Fischer DF, van Leeuwen FW and Hol EM (2004) Protein quality control in Alzheimer's disease by the ubiquitin proteasome system. Prog Neurobiol 74, 249-270
DOI
|
28 |
Lee MJ, Lee JH and Rubinsztein DC (2013) Tau degradation: the ubiquitin-proteasome system versus the autophagy-lysosome system. Prog Neurobiol 105, 49-59
DOI
|
29 |
Petrucelli L, Dickson D, Kehoe K et al (2004) CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum Mol Genet 13, 703-714
DOI
|
30 |
Flach K, Ramminger E, Hilbrich I et al (2014) Axotrophin/MARCH7 acts as an E3 ubiquitin ligase and ubiquitinates tau protein in vitro impairing microtubule binding. Biochim Biophys Acta 1842, 1527-1538
DOI
|
31 |
David DC, Layfield R, Serpell L, Narain Y, Goedert M and Spillantini MG (2002) Proteasomal degradation of tau protein. J Neurochem 83, 176-185
DOI
|
32 |
Grune T, Botzen D, Engels M et al (2010) Tau protein degradation is catalyzed by the ATP/ubiquitin-independent 20S proteasome under normal cell conditions. Arch Biochem Biophys 500, 181-188
DOI
|
33 |
Mori H, Kondo J and Ihara Y (1987) Ubiquitin is a component of paired helical filaments in Alzheimer's disease. Science 235, 1641-1644
DOI
|
34 |
Perry G, Friedman R, Shaw G and Chau V (1987) Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proc Natl Acad Sci U S A 84, 3033-3036
DOI
|
35 |
Wille H, Drewes G, Biernat J, Mandelkow EM and Mandelkow E (1992) Alzheimer-like paired helical filaments and antiparallel dimers formed from microtubule-associated protein tau in vitro. J Cell Biol 118, 573-584
DOI
|
36 |
Cripps D, Thomas SN, Jeng Y, Yang F, Davies P and Yang AJ (2006) Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-Tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation. J Biol Chem 281, 10825-10838
DOI
|
37 |
Morishima-Kawashima M, Hasegawa M, Takio K, Suzuki M, Titani K and Ihara Y (1993) Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments. Neuron 10, 1151-1160
DOI
|
38 |
Paine S, Bedford L, Thorpe JR et al (2009) Immunoreactivity to Lys63-linked polyubiquitin is a feature of neurodegeneration. Neurosci Lett 460, 205-208
DOI
|
39 |
Tan JM, Wong ES, Kirkpatrick DS et al (2008) Lysine 63-linked ubiquitination promotes the formation and autophagic clearance of protein inclusions associated with neurodegenerative diseases. Hum Mol Genet 17, 431-439
DOI
|
40 |
Tan Z, Sun X, Hou FS et al (2007) Mutant ubiquitin found in Alzheimer's disease causes neuritic beading of mitochondria in association with neuronal degeneration. Cell Death Differ 14, 1721-1732
DOI
|
41 |
Fitzpatrick AWP, Falcon B, He S et al (2017) Cryo-EM structures of tau filaments from Alzheimer's disease. Nature 547, 185-190
DOI
|
42 |
Giannakopoulos P, Herrmann FR, Bussiere T et al (2003) Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 60, 1495-1500
DOI
|
43 |
Ethell DW (2010) An amyloid-notch hypothesis for Alzheimer's disease. Neuroscientist 16, 614-617
DOI
|
44 |
Hung SY and Fu WM (2017) Drug candidates in clinical trials for Alzheimer's disease. J Biomed Sci 24, 47
DOI
|
45 |
Wang Y and Mandelkow E (2016) Tau in physiology and pathology. Nat Rev Neurosci 17, 5-21
DOI
|
46 |
Min SW, Cho SH, Zhou Y et al (2010) Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 67, 953-966
DOI
|
47 |
Roth SY, Denu JM and Allis CD (2001) Histone acetyltransferases. Annu Rev Biochem 70, 81-120
DOI
|
48 |
Liu X, Wang L, Zhao K et al (2008) The structural basis of protein acetylation by the p300/CBP transcriptional coactivator. Nature 451, 846-850
DOI
|
49 |
Marmorstein R (2001) Structure of histone acetyltransferases. J Mol Biol 311, 433-444
DOI
|
50 |
Cohen TJ, Guo JL, Hurtado DE et al (2011) The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commun 2, 252
DOI
|
51 |
Dickey CA, Kamal A, Lundgren K et al (2007) The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J Clin Invest 117, 648-658
DOI
|
52 |
Kim JH, Kim E, Choi WH et al (2016) Inhibitory RNA Aptamers of Tau Oligomerization and Their Neuroprotective Roles against Proteotoxic Stress. Mol Pharm 13, 2039-2048
DOI
|
53 |
Karabiyik C, Lee MJ and Rubinsztein DC (2017) Autophagy impairment in Parkinson's disease. Essays Biochem 61, 711-720
DOI
|
54 |
Cohen TJ, Friedmann D, Hwang AW, Marmorstein R and Lee VM (2013) The microtubule-associated tau protein has intrinsic acetyltransferase activity. Nat Struct Mol Biol 20, 756-762
DOI
|
55 |
Dickey CA, Dunmore J, Lu B et al (2006) HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites. FASEB J 20, 753-755
DOI
|
56 |
Liu WK, Ksiezak-Reding H and Yen SH (1991) Abnormal tau proteins from Alzheimer's disease brains. Purification and amino acid analysis. J Biol Chem 266, 21723-21727
|
57 |
King MK, Pardo M, Cheng Y, Downey K, Jope RS and Beurel E (2014) Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments. Pharmacol Ther 141, 1-12
DOI
|
58 |
Braak E, Braak H and Mandelkow EM (1994) A sequence of cytoskeleton changes related to the formation of neurofibrillary tangles and neuropil threads. Acta Neuropathol 87, 554-567
DOI
|
59 |
Lucas JJ, Hernandez F, Gomez-Ramos P, Moran MA, Hen R and Avila J (2001) Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J 20, 27-39
DOI
|
60 |
Forlenza OV, Aprahamian I, de Paula VJ and Hajek T (2016) Lithium, a Therapy for AD: Current Evidence from Clinical Trials of Neurodegenerative Disorders. Curr Alzheimer Res 13, 879-886
DOI
|
61 |
Abraha A, Ghoshal N, Gamblin TC et al (2000) C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease. J Cell Sci 113 Pt 21, 3737-3745
|
62 |
Morris M, Knudsen GM, Maeda S et al (2015) Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice. Nat Neurosci 18, 1183-1189
DOI
|
63 |
Alonso AD, Zaidi T, Novak M, Barra HS, Grundke-Iqbal I and Iqbal K (2001) Interaction of tau isoforms with Alzheimer's disease abnormally hyperphosphorylated tau and in vitro phosphorylation into the disease-like protein. J Biol Chem 276, 37967-37973
|
64 |
Wolfe MS (2009) Tau mutations in neurodegenerative diseases. J Biol Chem 284, 6021-6025
DOI
|
65 |
Flores-Rodriguez P, Ontiveros-Torres MA, Cardenas-Aguayo MC et al (2015) The relationship between truncation and phosphorylation at the C-terminus of tau protein in the paired helical filaments of Alzheimer's disease. Front Neurosci 9, 33
|
66 |
Peeraer E, Bottelbergs A, Van Kolen K et al (2015) Intracerebral injection of preformed synthetic tau fibrils initiates widespread tauopathy and neuronal loss in the brains of tau transgenic mice. Neurobiol Dis 73, 83-95
DOI
|
67 |
Guo JL and Lee VM (2013) Neurofibrillary tangle-like tau pathology induced by synthetic tau fibrils in primary neurons over-expressing mutant tau. FEBS Lett 587, 717-723
DOI
|
68 |
Noble W, Hanger DP, Miller CC and Lovestone S (2013) The importance of tau phosphorylation for neurodegenerative diseases. Front Neurol 4, 83
|
69 |
Matsunaga S, Kishi T, Annas P, Basun H, Hampel H and Iwata N (2015) Lithium as a Treatment for Alzheimer's Disease: A Systematic Review and Meta-Analysis. J Alzheimers Dis 48, 403-410
DOI
|
70 |
Yu Y, Run X, Liang Z et al (2009) Developmental regulation of tau phosphorylation, tau kinases, and tau phosphatases. J Neurochem 108, 1480-1494
DOI
|
71 |
Sontag JM and Sontag E (2014) Protein phosphatase 2A dysfunction in Alzheimer's disease. Front Mol Neurosci 7, 16
|
72 |
Liu F, Grundke-Iqbal I, Iqbal K and Gong CX (2005) Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci 22, 1942-1950
DOI
|
73 |
Luo Y, Ma B, Nussinov R and Wei G (2014) Structural Insight into Tau Protein's Paradox of Intrinsically Disordered Behavior, Self-Acetylation Activity, and Aggregation. J Phys Chem Lett 5, 3026-3031
DOI
|
74 |
Guo JL and Lee VM (2011) Seeding of normal Tau by pathological Tau conformers drives pathogenesis of Alzheimer-like tangles. J Biol Chem 286, 15317-15331
DOI
|
75 |
Nubling G, Bader B, Levin J, Hildebrandt J, Kretzschmar H and Giese A (2012) Synergistic influence of phosphorylation and metal ions on tau oligomer formation and coaggregation with alpha-synuclein at the single molecule level. Mol Neurodegener 7, 35
DOI
|
76 |
Gong CX, Shaikh S, Wang JZ, Zaidi T, Grundke-Iqbal I and Iqbal K (1995) Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer disease brain. J Neurochem 65, 732-738
|
77 |
Gorsky MK, Burnouf S, Dols J, Mandelkow E and Partridge L (2016) Acetylation mimic of lysine 280 exacerbates human Tau neurotoxicity in vivo. Sci Rep 6, 22685
DOI
|
78 |
Irwin DJ, Cohen TJ, Grossman M et al (2012) Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies. Brain 135, 807-818
DOI
|
79 |
Santa-Maria I, Hernandez F, Martin CP, Avila J and Moreno FJ (2004) Quinones facilitate the self-assembly of the phosphorylated tubulin binding region of tau into fibrillar polymers. Biochemistry 43, 2888-2897
DOI
|
80 |
Choi TS, Lee J, Han JY et al (2018) Supramolecular Modulation of Structural Polymorphism in Pathogenic alpha-Synuclein Fibrils Using Copper(II) Coordination. Angew Chem Int Ed Engl 57, 3099-3103
DOI
|
81 |
Goedert M, Spillantini MG, Jakes R, Rutherford D and Crowther RA (1989) Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 3, 519-526
DOI
|
82 |
Mandelkow EM and Mandelkow E (1998) Tau in Alzheimer's disease. Trends Cell Biol 8, 425-427
DOI
|
83 |
Andreadis A (2006) Misregulation of tau alternative splicing in neurodegeneration and dementia. Prog Mol Subcell Biol 44, 89-107
|
84 |
Goedert M, Cohen ES, Jakes R and Cohen P (1992) p42 MAP kinase phosphorylation sites in microtubule-associated protein tau are dephosphorylated by protein phosphatase 2A1. Implications for Alzheimer's disease [corrected]. FEBS Lett 312, 95-99
DOI
|
85 |
Kyte J and Doolittle RF (1982) A simple method for displaying the hydropathic character of a protein. J Mol Biol 157, 105-132
DOI
|
86 |
Kopke E, Tung YC, Shaikh S, Alonso AC, Iqbal K and Grundke-Iqbal I (1993) Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J Biol Chem 268, 24374-24384
|
87 |
Perez M, Hernandez F, Lim F, Diaz-Nido J and Avila J (2003) Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J Alzheimers Dis 5, 301-308
DOI
|
88 |
Noble W, Planel E, Zehr C et al (2005) Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A 102, 6990-6995
DOI
|
89 |
Avila J (2006) Tau phosphorylation and aggregation in Alzheimer's disease pathology. FEBS Lett 580, 2922-2927
DOI
|
90 |
Gong CX, Singh TJ, Grundke-Iqbal I and Iqbal K (1993) Phosphoprotein phosphatase activities in Alzheimer disease brain. J Neurochem 61, 921-927
DOI
|
91 |
Choi WH, de Poot SA, Lee JH et al (2016) Open-gate mutants of the mammalian proteasome show enhanced ubiquitin-conjugate degradation. Nat Commun 7, 10963
DOI
|
92 |
Han DH, Na HK, Choi WH et al (2014) Direct cellular delivery of human proteasomes to delay tau aggregation. Nat Commun 5, 5633
DOI
|
93 |
Jiang Y, Lee J, Lee JH et al (2016) The arginylation branch of the N-end rule pathway positively regulates cellular autophagic flux and clearance of proteotoxic proteins. Autophagy 12, 2197-2212
DOI
|